View ValuationPentixapharm Holding 将来の成長Future 基準チェック /06Pentixapharm Holdingの収益は年間13.4%で減少すると予測されていますが、年間収益は年間65.6%で増加すると予想されています。EPS は年間13.3%で減少すると予想されています。主要情報-13.4%収益成長率-13.32%EPS成長率Medical Equipment 収益成長17.1%収益成長率65.6%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日15 Jul 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 10Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary AldosteronismPentixapharm Holding AG received notice from the U.S. Food and Drug Administration (FDA) that Fast Track designation has been granted to its development candidate [68Ga]Ga-PentixaFor for the diagnosis of patients with hypertension and underlying primary aldosteronism. In its notification, the FDA determined that Pentixapharm's request meets the criteria for Fast Track designation and that [68Ga]Ga-PentixaFor is accordingly designated as a Fast Track product for the diagnostic subtyping of adult patients with confirmed primary aldosteronism. Fast Track designation is intended to facilitate the development and review of products that address serious conditions and have the potential to fill an unmet medical need. It provides opportunities for more frequent interaction with the FDA during development and may support a more efficient regulatory review process if the relevant criteria are met. The practical benefit of Fast Track designation lies above all in closer and more frequent interaction with the FDA, allowing development and submission questions to be clarified early and the regulatory process to be prepared efficiently. The FDA's specific designation relates to the diagnostic subtyping of adult patients with already confirmed primary aldosteronism, precisely the clinical decision point at which physicians must distinguish between potential surgical treatment and long-term medical therapy. The designation follows Pentixapharm's recent announcement that the Investigational New Drug (IND) application for the U.S. Phase 3 PANDA study of [68Ga]Ga-PentixaFor became effective following the FDA's 30-day review period, with the FDA allowing the study to proceed (“Study May Proceed”). [68Ga]Ga-PentixaFor addresses a central diagnostic bottleneck in primary aldosteronism and hypertension: non-invasive subtyping to guide the treatment decision between surgery and chronic medical therapy. Pentixapharm is preparing to initiate its pivotal Phase 3 PANDA study in the United States. PANDA is designed to evaluate [68Ga]Ga-PentixaFor PET/CT as a non-invasive imaging approach to help identify patients with unilateral primary aldosteronism. This distinction is clinically important because unilateral disease may be treated with surgical removal of the affected adrenal gland in selected patients, while bilateral disease generally requires long-term medical therapy. Primary aldosteronism is one of the most common and substantially underdiagnosed causes of secondary hypertension. The condition occurs when one or both adrenal glands produce too much aldosterone, a hormone that can drive high blood pressure and increase cardiovascular risk. For patients, the key treatment question is not only whether primary aldosteronism is present, but whether excess aldosterone production is coming from one adrenal gland or both. This makes accurate subtyping central to treatment selection and creates a major diagnostic bottleneck in the current care pathway. [68Ga]Ga-PentixaFor is designed to target CXCR4, a biological receptor shown to be strongly expressed in aldosterone-producing adrenal lesions. By visualizing CXCR4 expression with PET/CT, Pentixapharm aims to support a more precise and patient-friendly diagnostic pathway that can help physicians guide patients toward the appropriate treatment option. [68Ga]Ga-PentixaFor is a novel gallium-68-labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 using high-resolution PET/CT imaging. Clinical experience with [68Ga]Ga-PentixaFor PET/CT in more than 2,000 patients across different indications has demonstrated its ability to non-invasively image CXCR4 expression in vivo. Pentixapharm is evaluating this established CXCR4 imaging approach in primary aldosteronism, where molecular characterization of adrenal lesions may help address limitations of conventional anatomical imaging. Recent research has shown strong CXCR4 overexpression in aldosterone-producing adrenal tumors, supporting its potential relevance for identifying unilateral disease. Primary aldosteronism (PA) is increasingly recognized as one of the most common and significantly underdiagnosed endocrine disorders worldwide and a leading cause of secondary hypertension. Recent international and Endocrine Society guidelines have expanded recommendations for PA screening, reflecting growing evidence that the disease may affect approximately 5–10% of all patients with hypertension and up to 20–30% of those with treatment-resistant hypertension. Given the high prevalence of hypertension in the United States and globally, even modest improvements in PA detection and subtyping could translate into a meaningfully larger diagnosed and treatment-directed patient population. As awareness, screening, and targeted treatment options continue to advance, the diagnostic landscape for PA is undergoing a fundamental transformation. This shift has the potential to expand the addressable patient population from a highly selected subgroup to millions of patients globally, creating a substantial opportunity for innovative diagnostic approaches aimed at improving disease detection, patient stratification, and treatment selection.お知らせ • Jul 03Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million.Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 11,020,212 Price\Range: €1.85 Transaction Features: Rights Offering業績と収益の成長予測OTCPK:PTPD.F - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028N/A-24-15-20212/31/2027N/A-23-21-19212/31/2026N/A-22-10-1723/31/20260-16-15-15N/A12/31/20251-17-19-18N/A9/30/20252-26-24-22N/A6/30/2025-1-20-13-13N/A3/31/20251-16-10-10N/A1/1/20252-13-7-7N/A6/30/20244-5-11-7N/A3/31/20247-8-7-2N/A12/31/20237-8-32N/A12/31/20224-2-6-2N/A12/31/20213-2-4-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PTPD.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: PTPD.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: PTPD.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: PTPD.F来年は収益がないと予測されています。高い収益成長: PTPD.F来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PTPD.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 22:41終値2026/06/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pentixapharm Holding AG 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Roger BeckerBankM AGSimon KellerNuWays AG
お知らせ • Jul 10Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary AldosteronismPentixapharm Holding AG received notice from the U.S. Food and Drug Administration (FDA) that Fast Track designation has been granted to its development candidate [68Ga]Ga-PentixaFor for the diagnosis of patients with hypertension and underlying primary aldosteronism. In its notification, the FDA determined that Pentixapharm's request meets the criteria for Fast Track designation and that [68Ga]Ga-PentixaFor is accordingly designated as a Fast Track product for the diagnostic subtyping of adult patients with confirmed primary aldosteronism. Fast Track designation is intended to facilitate the development and review of products that address serious conditions and have the potential to fill an unmet medical need. It provides opportunities for more frequent interaction with the FDA during development and may support a more efficient regulatory review process if the relevant criteria are met. The practical benefit of Fast Track designation lies above all in closer and more frequent interaction with the FDA, allowing development and submission questions to be clarified early and the regulatory process to be prepared efficiently. The FDA's specific designation relates to the diagnostic subtyping of adult patients with already confirmed primary aldosteronism, precisely the clinical decision point at which physicians must distinguish between potential surgical treatment and long-term medical therapy. The designation follows Pentixapharm's recent announcement that the Investigational New Drug (IND) application for the U.S. Phase 3 PANDA study of [68Ga]Ga-PentixaFor became effective following the FDA's 30-day review period, with the FDA allowing the study to proceed (“Study May Proceed”). [68Ga]Ga-PentixaFor addresses a central diagnostic bottleneck in primary aldosteronism and hypertension: non-invasive subtyping to guide the treatment decision between surgery and chronic medical therapy. Pentixapharm is preparing to initiate its pivotal Phase 3 PANDA study in the United States. PANDA is designed to evaluate [68Ga]Ga-PentixaFor PET/CT as a non-invasive imaging approach to help identify patients with unilateral primary aldosteronism. This distinction is clinically important because unilateral disease may be treated with surgical removal of the affected adrenal gland in selected patients, while bilateral disease generally requires long-term medical therapy. Primary aldosteronism is one of the most common and substantially underdiagnosed causes of secondary hypertension. The condition occurs when one or both adrenal glands produce too much aldosterone, a hormone that can drive high blood pressure and increase cardiovascular risk. For patients, the key treatment question is not only whether primary aldosteronism is present, but whether excess aldosterone production is coming from one adrenal gland or both. This makes accurate subtyping central to treatment selection and creates a major diagnostic bottleneck in the current care pathway. [68Ga]Ga-PentixaFor is designed to target CXCR4, a biological receptor shown to be strongly expressed in aldosterone-producing adrenal lesions. By visualizing CXCR4 expression with PET/CT, Pentixapharm aims to support a more precise and patient-friendly diagnostic pathway that can help physicians guide patients toward the appropriate treatment option. [68Ga]Ga-PentixaFor is a novel gallium-68-labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 using high-resolution PET/CT imaging. Clinical experience with [68Ga]Ga-PentixaFor PET/CT in more than 2,000 patients across different indications has demonstrated its ability to non-invasively image CXCR4 expression in vivo. Pentixapharm is evaluating this established CXCR4 imaging approach in primary aldosteronism, where molecular characterization of adrenal lesions may help address limitations of conventional anatomical imaging. Recent research has shown strong CXCR4 overexpression in aldosterone-producing adrenal tumors, supporting its potential relevance for identifying unilateral disease. Primary aldosteronism (PA) is increasingly recognized as one of the most common and significantly underdiagnosed endocrine disorders worldwide and a leading cause of secondary hypertension. Recent international and Endocrine Society guidelines have expanded recommendations for PA screening, reflecting growing evidence that the disease may affect approximately 5–10% of all patients with hypertension and up to 20–30% of those with treatment-resistant hypertension. Given the high prevalence of hypertension in the United States and globally, even modest improvements in PA detection and subtyping could translate into a meaningfully larger diagnosed and treatment-directed patient population. As awareness, screening, and targeted treatment options continue to advance, the diagnostic landscape for PA is undergoing a fundamental transformation. This shift has the potential to expand the addressable patient population from a highly selected subgroup to millions of patients globally, creating a substantial opportunity for innovative diagnostic approaches aimed at improving disease detection, patient stratification, and treatment selection.
お知らせ • Jul 03Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million.Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 11,020,212 Price\Range: €1.85 Transaction Features: Rights Offering